Skip to main content

NAFLD, NASH and liver cancer.

Publication ,  Journal Article
Michelotti, GA; Machado, MV; Diehl, AM
Published in: Nat Rev Gastroenterol Hepatol
November 2013

NAFLD affects a large proportion of the US population and its incidence and prevalence are increasing to epidemic proportions around the world. As with other liver diseases that cause cirrhosis, NAFLD increases the risk of liver cancer, a disease with poor outcomes and limited therapeutic options. The incidences of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma are also rising, and HCC is now the leading cause of obesity-related cancer deaths in middle-aged men in the USA. In this Review, we summarize the correlations between liver cancer and NAFLD-related cirrhosis, and the role of the metabolic syndrome in the development of liver cancer from diverse aetiologies, including HCV-mediated cirrhosis. Recent advances in understanding the progression of NAFLD to HCC from preclinical models will also be discussed. Targeted genetic manipulation of certain metabolic or stress-response pathways, including one-carbon metabolism, NF-κB, PTEN and microRNAs, has been valuable in elucidating the pathways that regulate carcinogenesis in NAFLD. Although tremendous advances have occurred in the identification of diagnostic and therapeutic opportunities to reduce the progression of NAFLD, considerable gaps in our knowledge remain with regard to the mechanisms by which NAFLD and its risk factors promote liver cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Gastroenterol Hepatol

DOI

EISSN

1759-5053

Publication Date

November 2013

Volume

10

Issue

11

Start / End Page

656 / 665

Location

England

Related Subject Headings

  • Risk Factors
  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Metabolic Syndrome
  • Liver Neoplasms
  • Humans
  • Gastroenterology & Hepatology
  • Fatty Liver
  • Disease Models, Animal
  • Diabetes Mellitus, Type 2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013). NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol, 10(11), 656–665. https://doi.org/10.1038/nrgastro.2013.183
Michelotti, Gregory A., Mariana V. Machado, and Anna Mae Diehl. “NAFLD, NASH and liver cancer.Nat Rev Gastroenterol Hepatol 10, no. 11 (November 2013): 656–65. https://doi.org/10.1038/nrgastro.2013.183.
Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656–65.
Michelotti, Gregory A., et al. “NAFLD, NASH and liver cancer.Nat Rev Gastroenterol Hepatol, vol. 10, no. 11, Nov. 2013, pp. 656–65. Pubmed, doi:10.1038/nrgastro.2013.183.
Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656–665.

Published In

Nat Rev Gastroenterol Hepatol

DOI

EISSN

1759-5053

Publication Date

November 2013

Volume

10

Issue

11

Start / End Page

656 / 665

Location

England

Related Subject Headings

  • Risk Factors
  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Metabolic Syndrome
  • Liver Neoplasms
  • Humans
  • Gastroenterology & Hepatology
  • Fatty Liver
  • Disease Models, Animal
  • Diabetes Mellitus, Type 2